1. 1) Johnson SW, O'Dwyer PJ, “Pharmacology of cancer chemotherapy: cisplatin and its analogues. In: Cancer. Principles and practice of oncology” 7th ed, De Vita VT Jr, Hellman S, Rosenberg SA (Eds), Lippincott Williams & Wilkins, Philadelphia, 2005, pp344-358.
2. 3) Brock J, Alberts DS, Safe, rapid administration of cisplatin in the outpatient clinic, Cancer Treat Rep, 1986, 70, 1409-1414.
3. 4) Dana R, Kachhwaha VS, Comparison of oral and intravenous hydration and diuretic, choice for protecting cisplatin induced nephrotoxicity, Indian J Cancer, 1996, 33, 168-170.
4. 5) Saint-Lorant G, Madelaine J, Galais MP, Thierry L, Chédru-Legros V, Hydration of patients treated with cisplatin: practical investigation and establishment of a protocol, Therapie, 2005, 60, 499-505.
5. 6) Yamada K, Yoshida T, Zaizen Y, Okayama Y, Naito Y, Yamashita F, Takeoka H, Mizoguchi Y, Yamada K, Azuma K, Clinical practice in management of hydration for lung cancer patients receiving cisplatin-based chemotherapy in Japan: a questionnaire survey, Jpn J Clin Oncol, 2011, 41, 1308-1311.